EZ Cap™ Firefly Luciferase mRNA
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
EZ Cap™ Firefly Luciferase mRNA will express luciferase protein once entering cells, which is initially extracted from firefly Photinus pyralis. This enzyme catalyzes ATP-dependent D-luciferin oxidation and lead to yield chemiluminescence at about 560 nm wavelength. Firefly Luciferase is a frequently used bioluminescent reporter for gene regulation and function study. It is applicable in assays for mRNA delivery, translation efficiency, cell viability and in vivo imaging etc.
EZ Cap™ Firefly Luciferase mRNA is provided at a concentration of 1mg/ml. It is co-transcriptional capped by EZ Cap™ Reagent AG (Catalog No.B8176) which generates a cap 1 structure with high efficiency. Cap 1 structure is more ideal for mammalian systems and possesses higher transcription efficiency than Cap 0 structure (ARCA and mCap). The addition of poly (A) tail increases the stability and lifetime of the mRNA in vitro and in vivo. Poly (A) tail also plays an important role in enhancing the efficiency of translation initiation.
All the modifications are intention to mimics a fully processed mature mRNA. EZ Cap™ Firefly Luciferase mRNA is an ideal product to observing mRNA delivery, translation and other behaviors.
- 1. Yixuan Huang, Jiacai Wu, et al. "Quaternization drives spleen-to-lung tropism conversion for mRNA-loaded lipid-like nanoassemblies." Theranostics. 2024 Jan 1;14(2):830-842. PMID: 38169552
- 2. Mingzhu Gao, Maoping Tang, et al. "Modulating Plaque Inflammation via Targeted mRNA Nanoparticles for the Treatment of Atherosclerosis." ACS Nano. 2023 Sep 26;17(18):17721-17739. PMID: 37669404
- 3. Min Li, Yixuan Huang, et al. "A PEG-lipid-free COVID-19 mRNA vaccine triggers robust immune responses in mice." Materials Horizons. PMID: 36468425
- 4. Shaoyan Gao, Xiaohe Li, et al. "PKM2 promotes pulmonary fibrosis by stabilizing TGF-β1 receptor I and enhancing TGF-β1 signaling." Sci Adv. 2022 Sep 23;8(38):eabo0987. PMID: 36129984
- 5. Y. Huang, M. Yang, et al. "Intracellular delivery of messenger RNA to macrophages with surfactant-derived lipid nanoparticles." Materials Today Advances.
- 6. Jiaxing Di, Zhili Du, et al. "Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size." Pharm Res. 2022 Jan;39(1):105-114. PMID: 35080707
- 7. Min Li , Sanpeng Li, et al. "Secreted Expression of mRNA-Encoded Truncated ACE2 Variants for SARS-CoV-2 via Lipid-Like Nanoassemblies." Adv Mater. 2021 Aug;33(34):e2101707. PMID: 34278613
mRNA Length | 1921 nucleotides | ||
Concentration | 1 mg/mL | ||
Buffer | 1 mM Sodium Citrate, pH 6.4 | Storage | -40°C or below |
General tips | 请将其于冰上溶解,并小心防止RNase污染降解。 尽可能避免反复冻融。 不要涡旋震荡。 首次使用时,将其轻柔离心并分成几份,可供单独使用。 使用不含RNase的试剂和耗材,使用适当的无RNase技术。 直至与转染试剂混合,才可加入含有血清的培养基中。 | ||
Shipping Condition | 试用装:干冰运输。 |